Загрузка...
Mavacamten has a differential impact on force generation in myofibrils from rabbit psoas and human cardiac muscle
Mavacamten (MYK-461) is a small-molecule allosteric inhibitor of sarcomeric myosins being used in preclinical/clinical trials for hypertrophic cardiomyopathy treatment. A better understanding of its impact on force generation in intact or skinned striated muscle preparations, especially for human ca...
Сохранить в:
| Опубликовано в: : | J Gen Physiol |
|---|---|
| Главные авторы: | , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Rockefeller University Press
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8077167/ https://ncbi.nlm.nih.gov/pubmed/33891673 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1085/jgp.202012789 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|